Form 4: Sarepta CFO Disposes Shares for Tax Obligations

Sarepta Therapeutics' Chief Financial Officer, Ryan Ho-Yan Wong, reported a disposition of 450 common shares to satisfy tax withholding obligations related to restricted stock unit vesting.

Summary

• Ryan Ho-Yan Wong, Chief Financial Officer of Sarepta Therapeutics, Inc. (SRPT), reported a transaction on March 2, 2026.
• The transaction involved the disposition of 450 shares of Sarepta Therapeutics Common Stock.
• The shares were disposed of at a price of $16.2 per share.
• This disposition was made to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs) granted on March 1, 2024.
• Following this transaction, Ryan Ho-Yan Wong beneficially owns 135,595 shares of Common Stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It reports a routine, non-discretionary insider transaction for tax purposes, which does not indicate any change in company fundamentals or management's outlook.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that this type of insider transaction, where shares are disposed of to cover tax liabilities upon the vesting of equity awards like Restricted Stock Units (RSUs), is a routine and non-discretionary event common among executives in publicly traded companies across various industries. It typically does not reflect a change in the executive's investment sentiment or the company's operational performance.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in company fundamentals or insider sentiment.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary transaction by an insider to cover tax obligations related to equity compensation. It does not reflect a change in investment sentiment or company fundamentals, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Sarepta Therapeutics, SRPT, Insider Transaction, Form 4, CFO, Stock Disposition, RSU Vesting, Tax Withholding